Strategic Focus Clinical-stage biotech with a diverse infectious disease pipeline, including Betacoronaviruses, Dengue, Universal Influenza, and intracellular bacteria, plus patch-based therapeutics and oncology/ cardiometabolic targets. This breadth signals multiple potential partnership and licensing opportunities across infectious disease vaccines, immunotherapies, and niche therapeutics.

Innovative Delivery Proprietary skin-delivery platform combining MHC Class I ligandome, ultrasmall nanocluster carriers, and MAP transdermal patches, enabling non-invasive administration. Opportunities exist for collaborations with pharma seeking alternative delivery methods to improve compliance, logistically simpler vaccination campaigns, and rapid scaling.

Geographic Footprint Operations across UK and US with R&D, GMP manufacturing in the UK, and manufacturing facilities in California, plus an operating subsidiary in Pennsylvania. This provides regional alignment for North America and Europe-focused partnerships, pilot programs, and potential manufacturing partnerships or tech transfers.

Financial Profile Revenue in the low-to-mid single digits with modest funding, indicating a growth-oriented partner open to collaboration, co-development, or licensing deals to accelerate clinical milestones and broaden manufacturing reach without heavy upfront risk.

Strategic Partners Recent tech acquisition of microneedle array patch capability from Zosano Pharma suggests openness to external tech integration and strategic alliances. This signals potential for co-development, technology licensing, or hybrid programs leveraging existing platform assets.